MoonLake Immunotherapeutics Reports Q3 GAAP EPS of -$0.93
MoonLake Immunotherapeutics (MLTX) reported third-quarter GAAP earnings per share of -$0.93, missing analyst expectations by $0.15. Despite the earnings miss, the biotechnology company maintains a strong liquidity position, ending the quarter with $498.5 million in cash, cash equivalents, and short-term marketable debt securities. The company projects its current capital reserves will provide a cash runway extending into mid-2028. Furthermore, MoonLake has access to up to $400 million in non-dilutive funding through an existing debt facility with Hercules Capital, providing additional financial flexibility as it advances its clinical and regulatory programs.
Topics: biotechnology cash runway earnings miss financial results